Apr 3, 2025, 06:36
MSS Colorectal Cancer – New Immunotherapy Strategies and Metastatic Impact
In the inaugural event of the Global Cancer Movement, initiated by OncoDaily, Marwan Fakih explores groundbreaking research on identifying patients with microsatellite-stable (MSS) colorectal cancer (CRC) who may respond to immunotherapy, despite the absence of strong tissue biomarkers.
Key discussion points include:
- Clinical signatures that predict immunotherapy response in MSS-CRC.
- The role of PD-1 and CTLA-4 inhibition in improving treatment outcomes.
- The impact of metastatic sites, with liver metastases linked to resistance.
- Findings from key studies, including JAMA Network (2021) and LEAP-017 trials.
- The potential of CTLA-4 inhibitors in enhancing responses in non-liver metastases.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 3, 2025, 05:51
Apr 3, 2025, 05:29
Apr 3, 2025, 03:54